Early apixaban administration considering the size of infarction and functional outcome in acute ischemic stroke.

ABSTRACT:

Background and purpose

Atrial fibrillation-related stroke (AF-stroke) is associated with an adverse prognosis, characterized by a high incidence of progression, recurrence, and hemorrhagic transformation. Our study aims to investigate the potential benefits of stratified early administration of apixaban, taking into account infarct size during the acute phase, in order to enhance functional outcomes.

Methods

We conducted this study at a tertiary referral stroke center, enrolling acute AF-stroke patients who received apixaban during the acute phase. Infarct size was categorized as small, medium, or large based on diffusion-weighted imaging. Patients were divided into two groups: standard initiation (apixaban initiation based on guidelines, i.e., small: 4 days, medium: 7 days,

SUBMITTER: Lee MH 

PROVIDER: S-EPMC10853473 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature